An Experimental Drug for Crohn's Disease

CCX282-B, also known as Traficet-EN®, is an investigational oral drug that is intended to target the underlying cause of Crohn's disease. Taken in by mouth , this promising new agent is undergoing evaluation in an international clinical trial being conducted by leading physicians at clinical sites in Australia, Brazil, Canada, Israel, South Africa and selected countries throughout Europe. Prior to the current study, five clinical trials have been completed so far with CCX282-B and 250 people have received the drug to date.

How does it work?
CCX282-B has a mode of action that addresses Crohn's disease in a completely different way than current treatments. CCX282-B is designed to block the inappropriate activity of specific immune cells in the intestine that cause inflammation and lead to Crohn's disease symptoms. Inflammation in the small intestine is believed to result in the flare ups of abdominal pain, cramps, weight loss and diarrhea associated with Crohn's disease.

Participating in the PROTECT-1 Clinical Trial

ChemoCentryx, Inc., a biopharmaceutical company developing many novel medicines, is working with clinicians from all over the world to evaluate CCX282-B in a clinical study known as PROTECT-1. The trial is designed to evaluate how effective and safe CCX282-B is in treating Crohn's disease compared to placebo. Patients who are currently experiencing moderate to severe symptoms may be eligible to participate.

To find out whether you may be eligible to participate in the PROTECT-1 study, please see www.clinicaltrials.gov and use the search term "CCX282-B". There you will find information on eligibility criteria and participating clinical trial sites.

Further questions? Please contact ChemoCentryx at
PROTECT-1@ChemoCentryx.com and one of our clinical trial specialists will assist you.